---
title: "2025 National Dialogue Closing Day: Representatives from foreign companies such as Eli Lilly, Pfizer, and Bristol Myers Squibb enter the venue"
type: "News"
locale: "zh-HK"
url: "https://longbridge.com/zh-HK/news/263919101.md"
description: "According to reporters from the on-site negotiations for the 2025 National Medical Insurance Directory and the price negotiations for innovative drugs with commercial insurance, around 8 a.m. on the morning of the fifth day of the 2025 National Negotiation, Qian Yun, Vice President of Pfizer Global Biopharmaceutical Commercial Group for China, De He Lan, President and General Manager of Eli Lilly China, and representatives from Bristol Myers Squibb and other foreign companies began to enter. Reporters learned that today is the last day of the 2025 National Negotiation schedule, and the negotiation results are expected to be released in early December 2025"
datetime: "2025-11-03T00:43:00.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/263919101.md)
  - [en](https://longbridge.com/en/news/263919101.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/263919101.md)
---

> 支持的語言: [简体中文](https://longbridge.com/zh-CN/news/263919101.md) | [English](https://longbridge.com/en/news/263919101.md)


# 2025 National Dialogue Closing Day: Representatives from foreign companies such as Eli Lilly, Pfizer, and Bristol Myers Squibb enter the venue

According to reporters at the 2025 National Medical Insurance Catalog on-site negotiations and commercial insurance innovative drug catalog price negotiations, around 8 a.m. on the morning of the fifth day of the 2025 National Negotiation, Qian Yun, Vice President of Pfizer Global Biopharmaceutical Commercial Group for China, De He Lan, President and General Manager of Eli Lilly China, and representatives from Bristol Myers Squibb and other foreign companies began to enter. Reporters learned that today is the last day of the 2025 National Negotiation schedule, and the negotiation results are expected to be released in early December 2025

### 相關股票

- [Eli Lilly (LLY.US)](https://longbridge.com/zh-HK/quote/LLY.US.md)
- [Pfizer (PFE.US)](https://longbridge.com/zh-HK/quote/PFE.US.md)
- [Bristol Myers Squibb (BMY.US)](https://longbridge.com/zh-HK/quote/BMY.US.md)

## 相關資訊與研究

- [Komprise storage tiering service pledges flash savings](https://longbridge.com/zh-HK/news/280692430.md)
- [Faro Announces Collaboration with Bristol Myers Squibb to Scale Autonomous AI in Clinical Development](https://longbridge.com/zh-HK/news/281192593.md)
- [Lilly to acquire Centessa Pharmaceuticals to advance treatments for sleep-wake disorders | LLY Stock News](https://longbridge.com/zh-HK/news/281171668.md)
- [Pfizer’s Swedish Ibrance Study: Fresh Real‑World Data Signal for PFE Investors](https://longbridge.com/zh-HK/news/281219504.md)
- [InSilico Medicine's Loss Widens in 2025; Enters Licensing Agreement With Eli Lilly](https://longbridge.com/zh-HK/news/280951810.md)